Do-Good Pharmas?

Carpenter, Dave
October 2003
H&HN: Hospitals & Health Networks;Oct2003, Vol. 77 Issue 10, p48
Trade Publication
Discusses the efforts of pharmaceutical companies to balance profit-making with social responsibility. Lending of medical personnel from Pfizer to developing countries to help fight HIV/AIDS; Campaign of Oxnam against Pfizer; Importance of reputation management for pharmaceutical companies.


Related Articles

  • No magic potion among Pfizer's drugs. Harrington, John // Crain's New York Business;04/23/2001, Vol. 17 Issue 17, p46 

    Reports on an increase in the earnings of New York City-based pharmaceutical firm Pfizer Inc. for the first quarter of the year 2001. Factors behind the increase; Percentage of revenue growth achieved by the firm; Business strategies to further increase the firm's earnings.

  • A Dose of Strong Medicine. P., Shankar // njbiz;6/23/2003, Vol. 16 Issue 25, p35 

    Focuses on the financial performance of the pharmaceutical company Pfizer in New York City. Income posted by the company in 2002; Plans of the company for its business; Drugs that face the loss of their patents.

  • Pfizer Offers Solid 3Q Results.  // Chemical Market Reporter;10/22/2001, Vol. 260 Issue 15, p3 

    Reports on the performance of pharmaceutical company Pfizer as of October 22, 2001. Factors contributing to Pfizer's strong performance; Net income of the company in the third quarter of 2001; Percentage of the market held by the Pfizer drug Lipitor.

  • Pfizer Maintains Steady 3Q Growth.  // Chemical Market Reporter;10/21/2002, Vol. 262 Issue 14, p3 

    Reports on the growth in profits of the pharmaceutical company Pfizer Inc. in the third quarter of 2002. Percentage rise in the company's earnings; Percentage rise in sales of the company; Drugs that contributed to higher sales.

  • Pfizer India Ltd.--implementing restructuring programme.  // Chemical Business;Mar1998, Vol. 12 Issue 3, p80 

    Focuses on the financial performance of Pfizer India Ltd., a pharmaceutical company, for the fiscal year that ended March 1997. Sales; Net profits; Earning per share.

  • Medicine Man. McKinnell, Hank; Gibbs, Lisa // Money;Jun2001, Vol. 30 Issue 6, p37 

    Presents an interview with Henry McKinnell, chief executive officer of pharmaceutical company Pfizer. Competition between Pfizer's drug Lipitor and Astra-Zeneca's Crestor; Product launches planned for 2001; Reasons for a slower revenue growth in 2000.

  • Johnson & Johnson and Pfizer show strong earnings growth. Martinez, Marialba // Caribbean Business;4/25/2002, Vol. 30 Issue 17, p16 

    Reports on the financial performance of drug companies Johnson & Johnson and Pfizer Co. during the first quarter of 2002. Corporate profits; Sales; Growth targets and strategies.

  • PFIZER'S EARNINGS SURGE, DRUG FIRMS' GROWTH MODERATE.  // Caribbean Business;10/26/1995, Vol. 23 Issue 43, p58 

    Reports on the financial performance of Pfizer Inc. in the third quarter of 1995. Increase in earnings; Net income posted; Favorable exchange rates' addition of sales growth; Strong sales of products such as the antidepressant Zoloft and the heart medication Norvasc.

  • Akzo Nobel Strives to Boost Pharma With Pfizer Deal. Jarvis, Lisa // Chemical Market Reporter;11/3/2003, Vol. 264 Issue 15, p8 

    Reports on the agreement between the pharmaceutical firms Akzo Nobel Pharmaceutical and Pfizer Inc. in the U.S. Sales performance of Akzo Nobel; Benefits of the deal for the companies; Business strategies of Akzo Nobel.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics